China Pharma HoldingCPHI -10.97%26 Days Payable is 112.79 as of Mar. 2026, which is 152% above its 10-year median of 44.69. GuruFocus rates CPHI with a GF Score™ of 26/100 and a GF Value™ of $0.24 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, China Pharma Holding ranks worse than 62.8% on this metric.
The historical rank and industry rank for China Pharma Holding's Days Payable or its related term are showing as below:
CPHI'
s Days Payable Range Over the Past 10 Years
Min: 33.36 Med: 44.69 Max: 81.25
Current: 66.95
During the past 13 years, China Pharma Holding's highest Days Payable was 81.25. The lowest was 33.36. And the median was 44.69.
CPHI's Days Payable is ranked worse than 62.8% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.455
vs CPHI: 66.95
China Pharma Holding's Days Payable
increased
from Mar. 2025 (27.73) to Mar. 2026 (112.79).
It may suggest that China Pharma Holdingdelayed paying its suppliers.
China Pharma Holding Days Payable Related Terms
China Pharma Holding Days Payable Historical Data
* Premium members only.
The historical data trend for China Pharma Holding's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Pharma Holding Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Days Payable distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
China Pharma Holding's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding (CPHI) has a Days Payable of 112.79 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China Pharma Holding and its competitors. This is 152% above median its historical median of 44.69. Over the past decade, China Pharma Holding's Days Payable has ranged from 33.36 to 81.25. According to the industry distribution chart, China Pharma Holding ranks #579 out of 922 companies in the Drug Manufacturers industry, placing it in the top 62.8%.
Is China Pharma Holding's Days Payable too high?
China Pharma Holding's current Days Payable of 112.79 is 152% above median its 10-year median of 44.69. Over the past 10 years, this metric has ranged from a low of 33.36 to a high of 81.25. The Drug Manufacturers industry median Days Payable is 90.46. China Pharma Holding's value of 112.79 is 24.7% above this industry median. Based on the distribution chart, China Pharma Holding ranks #579 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, China Pharma Holding has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's Days Payable compare to TXMD and RMTI?
According to the Drug Manufacturers industry distribution chart, China Pharma Holding ranks #579 out of 922 companies for Days Payable. This places China Pharma Holding in the lower half of its industry. The industry median Days Payable is 90.46. China Pharma Holding's value of 112.79 is 24.7% above this benchmark. Historically, China Pharma Holding's own Days Payable has ranged from 33.36 to 81.25 over the past decade. While the company's 10-year median is 44.69 vs. the industry median of 90.46, China Pharma Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.46, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Pharma Holding's current Days Payable of 112.79 is 24.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China Pharma Holding and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Pharma Holding's current Days Payable is 112.79, which is 152% above median its own 10-year median of 44.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
Based on GuruFocus' analysis, China Pharma Holding (CPHI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.57 — trading 137.5% above its estimated fair value. The current Days Payable is 112.79, which is 152% above median its 10-year median of 44.69 and 24.7% above the Drug Manufacturers industry median of 90.46. China Pharma Holding's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For China Pharma Holding (CPHI), the current Days Payable is 112.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Pharma Holding (CPHI) Overvalued in 2026?
Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued.
The current stock price of $0.57 is trading 137.5% above its estimated GF Value™ of $0.24.
GuruFocus considers China Pharma Holding to be Significantly Overvalued.
Key valuation signals for CPHI:
Days Payable: 112.79 (152% above median its 10-year median of 44.69)
GF Value™: $0.24 vs. price of $0.57 (137.5% above fair value)
Industry Position: 24.7% above the Drug Manufacturers median (#579 of 922)
No single metric tells the full story. See the CPHI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score
Get the complete analysis for CPHI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHI has been successfully added to your 
